BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters - 2Which Kind of Pet Makes the Incomparable Buddy?
- 3They grew up with 'almond moms.' Now, they dread going home for the holidays.
- 435 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- 5Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- Brazil passes anti-gang law allowing seized crypto to fund security forces
- Defeating An inability to embrace success in Scholarly world: Individual Victories
- Map shows more than 1,900 measles cases across U.S.
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- How to watch 'A Charlie Brown Christmas' for free this weekend
- Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- Change Your Physical make-up: Compelling Activities for Muscle Building
- Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
